Cencora recently announced a definitive agreement to acquire the retina business of EyeSouth Partners to grow Retina Consultants of America (RCA). This strategic move is expected to strengthen Cencora’s position in the specialized ophthalmology market. This acquisition is in the form of a cash payment, which amounts to about $1.1 billion. Cencora aims to increase the clinical reach of Retina Consultants of America (RCA).
The acquisition includes affiliated retina physicians from across the United States. These specialists will join the existing network of Retina Consultants of America (RCA). EyeSouth Partners is a portfolio company of Olympus Partners. This deal allows Cencora to broaden its relationships with community providers.
Strategic Growth in Specialized Care
The deal aligns with Cencora’s long-term strategy to invest in specialty pharmaceutical services. It builds upon the company’s previous investments in the retina care space. Furthermore, the integration will help optimize market access to therapies. Cencora expects the acquisition to be slightly accretive to its adjusted diluted EPS.
“The affiliated retina physicians of EyeSouth Partners will join Cencora’s Retina Consultants of America,” the company stated. “This acquisition allows Cencora to build on its leadership in specialty.”
The transaction remains subject to customary closing conditions and regulatory approvals. Cencora does not expect the deal to close in its fiscal 2026. Transition teams are already working to ensure a smooth integration process for all clinics. The company remains focused on creating healthier futures through its pharmaceutical solutions. Investors should note that BofA Securities served as the lead financial advisor. This move marks another step in the growth of specialized medical services.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
